Meek, C.L. and Wallace, A.M. and Forrest, L.M. and McMillan, D.C.
The relationship between the insulin-like growth factor-1 axis, weight loss, an inflammation-based score and survival in patients with inoperable non-small cell lung cancer. Clinical Nutrition
ISSN 0261-5614

http://eprints.gla.ac.uk/7677/

Deposited on: 2 February 2010

The relationship between the insulin-like growth factor-1 axis, weight loss, an inflammation-based score and survival in patients with inoperable non-small cell lung cancer.

Claire L Meek [1], A Michael Wallace [2], Lynn M Forrest [1] and Donald C McMillan [1].

1. University Department of Surgery, Faculty of Medicine-University of Glasgow, Royal Infirmary, Glasgow, UK.

2. Department of Clinical Biochemistry, Royal Infirmary, Glasgow, UK.

Running Title: Insulin-like growth factor-1 axis in non-small cell lung cancer.

Correspondence to:

Professor Donald C McMillan,

University Department of Surgery, Faculty of Medicine-University of Glasgow

Royal Infirmary, Glasgow G31 2ER, United Kingdom.

Tel No: 0141 211 5435

Fax No: 0141 552 3229

Email: d.c.mcmillan@clinmed.gla.ac.uk

Abstract

Background and aims: The involvement of a systemic inflammatory response, as evidenced by the Glasgow Prognostic Score (GPS), is associated with weight loss and poor outcome in patients with non-small cell lung cancer. There is good evidence that nutritional and functional decline in patients with advanced malignant disease is associated with catabolic changes in metabolism. However, defects in anabolism may also contribute towards nutritional decline in patients with cancer. The aim of the present study was to examine the relationship between IGF-1 and IGFBP-3, performance status, mGPS and survival in patients with inoperable NSCLC.

Methods: 56 patients with inoperable NSCLC were studied. The plasma concentrations of IGF-1, IGFBP-3 and leptin were measured using ELISA and RIA.

Results: The patients were predominantly male (61%), over 60 years old (80%), with advanced (stage III or IV) disease (98%), with a BMI ≥ 20 (84%), an ECOG-ps of 0 or 1 (79%), a haemoglobin (59%) and white cell count (79%) in the reference range. On follow-up 43 patients died of their cancer. On univariate analysis, BMI ($p<0.05$), Stage ($p<0.05$), ECOG-ps ($p<0.05$), haemoglobin ($p<0.05$), white cell count ($p<0.05$) and mGPS ($p<0.05$) were associated with cancer specific survival. There was no association between age, sex, treatment, IGF-1, IGFBP-3, IGF-1:IGFBP-3 ratio, or leptin and cancer specific survival. With an increasing mGPS concentrations of haemoglobin ($p<0.005$) and IGFBP-3 ($p<0.05$) decreased. mGPS was not associated with either IGF-1($p>0.20$), or leptin ($p>0.20$).

Conclusions: In summary, the results of this study suggest that anabolism (IGF-1 axis) does not play a significant role in the relationship between nutritional and functional decline, systemic inflammation and poor survival in patients with inoperable NSCLC.

Non-standard abbreviations: GPS: Glasgow prognostic score, IGF-1: Insulin-like growth factor-1, IGFBP-3: Insulin-like growth factor binding protein –3, NSCLC: Non-small cell lung cancer

Key words: Insulin-like growth factor-1, IGF-binding protein-3, weight loss, C-reactive protein, albumin, non-small cell lung cancer.

Introduction

Non-small cell lung cancer (NSCLC) is the most common cause of cancer-related death in the world, responsible for over 600,000 deaths each year[1]. In the United Kingdom, there are over 30,000 new cases registered per year, with only 7% of these patients alive at five years[2]. Many patients present with advanced inoperable disease, have cachexia, poor performance status and poor survival[3].

Nutritional and functional decline in cancer patients is associated with disordered metabolism, particularly the development of a systemic inflammatory response[4,5]. This systemic inflammatory involvement, as evidenced by elevated circulating concentrations of C-reactive protein and hypoalbuminaemia (Glasgow Prognostic score, GPS), is a normal response to an insult which, when prolonged in cancer, becomes detrimental to the patient, being associated with cachexia, poor performance status and reduced survival in patients with a variety of common solid tumours[6-8]. These deleterious consequences have been attributed, in part, to the production of inflammatory cytokines, in particular interleukin 1-beta and interleukin-6[9-11], which exert a directly catabolic effect on skeletal muscle and other host tissues[12-13]. Indeed, Krzystek-Korpacka and colleagues[14] recently reported that the GPS was associated with increased weight loss and elevated concentrations of IL-1, IL-6, IL-8, TNF-alpha, VEGF-A and midkine concentrations.

However, although defects in anabolism may encourage and maintain this deleterious state of catabolism, few studies have addressed the relationship between the systemic inflammatory response and anabolic mediators of metabolism in patients with advanced cancer[15-17]. The insulin-like growth factor-1 (IGF-1) axis is an important regulator of anabolism, which may be deregulated in advanced cancer[15,18]. The majority of IGF-1 in human serum circulates in association with IGF-binding protein-3, which prolongs its half-life but reduces its bioactivity.

The aim of the present study was to examine the relationship between IGF-1, IGFBP-3, weight loss and the systemic inflammatory response in patients with inoperable non-small cell lung cancer.

Patients and Methods

Patients

      Patients presenting to a multidisciplinary oncology clinic at the Royal Infirmary between November 2003 and April 2004, with inoperable NSCLC were included in the study. All patients had cytologically or histologically confirmed disease and were staged on the basis of clinical findings, chest X-ray, and where appropriate, bronchoscopy, liver ultrasound, isotope bone scan and computerized tomography of the thorax, according to the American Thoracic Society TNM classification. Patients were excluded if they had any history of metabolic or endocrine disorders, or were on oral corticosteroid therapy. Healthy subjects were recruited from a cardiovascular risk factor clinic to form a control group.

      The study was approved by the Ethics Committee of Glasgow Royal Infirmary. All participants were informed of the purpose of the study prior to entry and gave written, informed consent.

Methods

      The body mass index (BMI), extent of weight loss and ECOG performance status were measured at the time of diagnosis. A fasting blood sample was taken at the clinic for routine laboratory analysis of white cell count and serum concentrations of haemoglobin, C-reactive protein, albumin and glucose. The inter- and intra-assay variability in each case was less than 10%. The minimal detectable concentration of C-reactive protein was 6mg/l.

      A further blood sample was taken, placed immediately on ice and centrifuged at 1000g for 15 minutes at 4°C. The plasma was then frozen at -20°C for batch analysis of circulating concentrations of IGF-1 and IGFBP-3.

      All measurements were carried out prior to treatment.

The enzyme-linked immunosorbant assay (ELISA) method was employed for quantification of IGF-1 and IGFBP-3. IGF-1 concentrations were measured using a commercial Octeia IGF-1 kit (Immunodiagnostic Systems, Boldon, UK) with a minimum detection limit of 1.9µg/L. IGFBP-3 concentrations measured using a commercial Quantikine ELISA kit (R&D Systems Europe Ltd, Abingdon, UK) with a minimum limit of detection limit of 0.04µg/L. All samples were analysed in duplicate and the mean value was calculated. The inter- and intra-assay variabilities were consistently less than 10%.

Leptin was quantified by an in-house radio-immunoassay, which has been described and validated elsewhere[19].

The GPS was constructed as previously described[7]. Briefly, patients with both an elevated C-reactive protein (>10mg/l) and hypoalbuminaemia (<35g/l) were allocated a score of 2. Patients with only one of these biochemical abnormalities were allocated a score of 1. Patients in whom neither of these abnormalities was present were allocated a score of 0. Recently, however, this has been modified based on evidence that hypoalbuminaemia, without an elevated C-reactive protein concentration, had no significant association with cancer specific survival. Therefore, patients with an elevated C-reactive protein were assigned a modified GPS score (mGPS) of 1 or 2 depending on the absence or presence of hypoalbuminaemia[20]. The rationale for the development of the GPS has been described previously[8] and the prognostic value of the combination of C-reactive protein and albumin has validated in a variety of common solid tumours[21].

Statistical Analysis

Grouping of the variables age, BMI, ECOG-ps, haemoglobin and white cell count was carried out using standard thresholds[22-24]. Survival analysis of the variables was performed using the Cox proportional hazard model. Deaths up to the end of February 2008 were

included in the analysis. Multivariate survival analysis, including all significant covariates

(P<0.05 to account for multiple comparisons) was performed using a stepwise backward

procedure to derive a final model of the variables that had a significant independent

relationship with survival. To remove a variable from the model, the corresponding P-value

had to be greater than 0.05. The relationships between the mGPS and other variables were

analysed using the Mantel–Haenszel (X^2) test for trend as appropriate. Analysis was

performed using SPSS software (SPSS Inc., Chicago, IL, USA).

Results

The characteristics of the 56 patients with inoperable NSCLC are shown in Table 1. The patients were predominantly male (61%), over 60 years old (80%) with advanced (stage III or IV) disease (98%). The majority of patients had a BMI $\geq$20 (84%), had an ECOG-ps of 0 or 1 (79%), had a haemoglobin (59%) and white cell count (79%) in the reference range.

The minimum follow-up was 48 months and the median follow-up of the survivors was 54 months. During this period, 43 (77%) died of their cancer. On univariate analysis, a low BMI ($p<0.05$), poor ECOG-ps ($p<0.05$) and low haemoglobin ($p<0.05$) were associated with cancer specific survival. In contrast, increasing TNM stage ($p<0.05$), white cell count ($p<0.05$) and mGPS ($p<0.05$) were associated with cancer specific survival. There was no association between age, sex, treatment, IGF-1, IGFBP-3, IGF-1:IGFBP-3 ratio, or leptin and cancer specific survival. On multivariate analysis of significant variables, only increasing white cell count ($p<0.05$), TNM stage ($p<0.005$) and mGPS ($p<0.001$) retained statistical significance.

The relationship between the mGPS and the clinicopathological characteristics of the patients with inoperable NSCLC are shown in Table 2). Age, sex, BMI, stage, ECOG-ps, white cell count, IGF-1, leptin and treatment were similar across the mGPS groups. With an increasing mGPS concentrations of haemoglobin ($p<0.005$) and IGFBP-3 ($p<0.05$) decreased. Also, there was a trend towards an increase in the IGF-1: IGFBP-3 ratio ($p<0.1$) as mGPS increased.

Discussion

In the present study there was no significant association between IGF-1, IGFBP-3, IGF-1:IGFBP-3 ratio, or leptin and survival. In contrast, the inflammation based prognostic score the mGPS, was independently associated with survival. Also with an increasing mGPS, IGFBP-3 concentrations were significantly decreased whereas there was no significant association with either IGF-1 or leptin. Taken together these results would suggest that anabolism (IGF-1 axis) plays a minor role in the relationship between nutritional and functional decline, systemic inflammation and poor survival in patients with inoperable NSCLC.

Recently there has been considerable speculation regarding the involvement of the IGF-1 axis in the aetiology of lean tissue loss in cancer[25,26]. IGF-1 is the downstream mediator of growth hormone (GH) action thus representing a key pathway in anabolism in health. Indeed, several studies have reported a reduction in circulating concentrations of IGF-1 in malignant disease, which may also have been be associated with nutritional decline[15,27,28]. In the present study, the median weight loss in patients was 1% which may explain why concentrations of IGF-1 were not significantly altered. The present study did not address the possibility of receptor resistance to IGF-1 action, and the possibility remains that ineffective IGF-1 action contributes towards cancer cachexia.

In the present study, the circulating concentrations of IGF-1 and IGFBP-3 of patients with inoperable NSCLC were not associated with body mass index or survival. However, when grouped according to mGPS score, levels of IGFBP-3 were significantly lower in patients with a higher mGPS. As IGFBP-3 binds to and sequesters IGF-1, reducing its bioactivity but prolonging its half-life, low concentrations of IGFBP-3 may contribute to an enhanced but short-lived action of IGF-1 in the patient. Also, Crown and co-workers[17] reported that circulating concentrations of IGF-1 and IGFBP-3 were unchanged in 30 patients

with NSCLC. They reported a negative correlation between the ratio of intact /total IGFBP-3 and the initial body weight of the cancer patients, suggesting that less IGFBP-3 proteolytic activity was associated with more weight loss, possibly by maintaining a high IGF-1 binding capacity, and reducing IGF-1 bioavailability to the tissues. However, it is possible the reduced concentrations of IGFBP-3 merely reflect the reduction in hepatic protein synthesis, following a systemic insult of this nature. IGFBP-3 is also known to inhibit cell growth independently of IGF-1 and may have a role in mediating apoptosis[29]. These results suggest that major alterations in the IGF-1 axis do not occur prior to significant weight loss or as a result of the systemic inflammatory response. Moreover, the present study questions whether IGF-1 axis has any association with prognosis in patients with inoperable NSCLC.

It is increasingly recognised that systemic inflammation is an important factor in the progressive loss of lean tissue in cancer patients[4,6,30]. In light of the above studies on the IGF-1 axis[15,17] it is possible that the increased systemic inflammation-driven demand for amino acids for increased hepatic synthesis of acute phase proteins[31], maintenance of albumin synthesis[32] and increased glucose production[33] is the main factor in the progressive loss of lean tissue in cancer patients. This is consistent with the evidence that moderation of the systemic inflammatory response is a useful approach to the management of the loss of weight and lean tissue in cancer patients[34,35].

The main limitations of the present study were that small numbers of patients were studied and only baseline measurements were included in the analysis. Furthermore, the patient recruitment from an outpatient clinic may have biased the population towards those with less weight loss and a better performance status since those patients with more weight loss and poorer performance status are less likely to attend such clinics. Therefore, longitudinal measurements of the relationship between weight loss, IGF-1, IGF-BP3 and the systemic inflammatory response during the progression of the disease would have been of

interest to corroborate the cross sectional results. Nevertheless, the present baseline data, at

diagnosis and with mature survival follow-up, are important as they have clinical relevance

since they identify patients who may benefit from early nutritional or therapeutic intervention.

In summary, the results of this study suggest that anabolism (IGF-1 axis) does not play

a significant role in the relationship between nutritional and functional decline, systemic

inflammation and poor survival in patients with inoperable NSCLC.

Conflict of interest

There is no conflict of interest to declare.

References

1. International Agency for Research on Cancer, 2000.

2. Cancerstats, 2004; www.cancerresearchuk.org.

3. Colinet B, Jacot W, Bertrand D, Lacombe S, Bozonnat MC, Daurès JP, Pujol JL. A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson's index. Br J Cancer 2005; 93: 1098-105.

4. Kotler DP. Cachexia. Ann Int Med 2000; 133: 622-634

5. MacDonald N. Cancer cachexia and targeting chronic inflammation: a unified approach to cancer treatment and palliative/ supportive care. J Support Oncol 2007; 5: 157-61.

6. Scott HR, McMillan DC, Forrest LM, Brown DJF, McArdle CS and Milroy R. The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Brit J Cancer. 2001; 87: 264-267.

7. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2003; 89: 1028-30.

8. McMillan DC. An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc 2008; 67: 257-262.

9. Laviano A, Meguid MM, Rossi-Fanelli F. Cancer anorexia: clinical implications, pathogenesis, and therapeutic strategies. Lancet Oncol 2003; 4: 686-694.

10. McKeown DJ, Brown DJF, Kelly A, Wallace AM, McMillan DC. The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer. Brit J Cancer 2004; 91: 1993-5.

11. Apte R, Krelin Y, Song X, Dotan S, Recih E, Elkabets M, Carmi Y, Dvorkin T, White R, Gayvoronsky L. Effects of micro-environment- and malignant cell-derived interleukin-1

in carcinogenesis, tumor invasiveness and tumour-host interactions. Eur J Cancer 2006; 42: 751-759.

12. MacDonald N, Easson AM, Mazurak VC, Dunn GP, Baracos VE. Understanding and managing cancer cachexia. J Am Coll Surg 2003; 197: 143-61.

13. Trikha M, Corringham R, Klein B, Rossi JF. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 2003; 9: 4653-65.

14. Krzystek-Korpacka M, Matusiewicz M, Diakowska D, Grabowskib K, Blachutc K, Koniecznyd D, Kustrzeba-Wojcickaa I, Terleckia G, Banas T. Acute-phase response proteins are related to cachexia and accelerated angiogenesis in gastroesophageal cancers. Clin Chem Lab Med 2008; 46: 359-364.

15. Simons JP, Schols AM, Buurman WA, Wouters EF. Weight loss and low body cell mass in males with lung cancer: relationship with systemic inflammation, acute-phase response, resting energy expenditure, and catabolic and anabolic hormones. Clin Sci (Lond) 1999; 97: 215-23.

16. Yoshikawa T, Yoshikazu N, Chiharu D, Makino T, Nomura K. Insulin resistance in patients with cancer: relationships with tumor site, tumor stage, body-weight loss, acute-phase response and energy expenditure. Nutrition 2001; 17: 590-593.

17. Crown AL, Cottle K, Lightman SL, Falk S, Mohamed-Ali V, Armstrong L, Millar AB, Holly JMP. What is the role of the insulin-like growth factor system in the pathophysiology of cancer cachexia, and how is it regulated? Clin Endocrinol 2002; 56: 723-733.

18. Kern KA, Norton JA. Cancer cachexia. J Parenter Enteral Nutr 1988; 12: 286-98.

19. McConway MG, Johnston D, Keppy A, Griffin D, Smith J, Wallace AM. Differences in circulating concentrations of total, free and bound leptin relate to gender and body composition in adult humans. Ann Clin Biochem 2000; 37: 717.

20. McMillan DC, Crozier JE, Canna K, Angerson WJ, McArdle CS. Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis 2007; 22: 881-886.

21. McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 2009;12:223-6.

22. Vigano A, Dorgan M, Buckingham J, Bruera E, Suarez-Almazor. Survival prediction in terminal cancer patients: a systematic review of the medical literature. Palliative Med 2000; 14: 363-374.

23. Maltoni M, Caraceni A, Brunelli C et al. Prognostic Factors in Advanced Cancer Patients: Evidence-Based Clinical Recommendations—A Study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol 2005; 23: 6240-6248.

24. Hauser CA, Stockler MR, Tattersall MHN. Prognostic factors in patients with recently diagnosed incurable cancer: a systematic review. Supp care Cancer 2006; 14: 999-1018.

25. Fouladiun M, Korner U, Bosaeus I, Daneryd P, Hyltander A, Lundholm KG. Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care--correlations with food intake, metabolism, exercise capacity, and hormones. Cancer 2005; 103: 2189-98.

26. Muscaritoli M, Bossola M, Aversa Z, Bellantone R, Rossi Fanelli F. Prevention and treatment of cancer cachexia: new insights into an old problem. Eur J Cancer 2006, 42: 31-41.

27. Smith WJ, Underwood LE, Keyes L, Clemmons DR. Use of Insulin-Like Growth Factor I (IGF-I) and IGF-Binding Protein Measurements to Monitor Feeding of Premature Infants. J Clin Endorcrinol Metab 1997; 82: 3982-3988.

28. Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocrine Rev 1994; 15: 80-101.

29. Rajah R, Valentinis B, Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 1997; 272: 12181-12188.

30. McMillan DC, Scott HR, Watson WS, Preston T, Milroy R, McArdle CS. Longitudinal study of the body cell mass and the inflammatory response in cancer patients. Nutr Cancer 1998; 31: 101-105.

31. Preston T, Slater C, McMillan DC, Falconer JS, Shenkin A, Fearon KS. Fibrinogen Synthesis Is Elevated in Fasting Cancer Patients with an Acute Phase Response. J Nutr 1998; 128: 1355-1360.

32. Fearon K, Falconer JS, Slater C, McMillan DC, Ross JA, Preston T. Albumin Synthesis Rates Are Not Decreased in Hypoalbuminemic Cachectic Cancer Patients With an Ongoing Acute-Phase Protein Response. Ann Surg 1998; 227: 249-254

33. Grimble RF. Inflammatory status and insulin resistance. Curr Opin Clin Nutr Met Care 2002; 5: 551-559.

34. Lundholm K, Gelin J, Hyltander A et al. Anti-inflammatory treatment may prolong survival in under-nourished patients with metastatic solid tumors. Cancer Res 1994; 54: 5602-5606.

35. McMillan DC, Wigmore SJ, Fearon KC, O'Gorman P, Wright CE, McArdle CS. A prospective randomised study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. Br J Cancer 1999; 79: 495-500.

Table 1. Prognostic factors of patients with NSCLC.

	Patients (n= 56)	Hazard ratio (95% CI)	P- value
Age (<60/ ≥60 years)	11/ 45	0.792 (0.38-1.66)	0.536
Sex (M/F)	34 / 22	1.13 (0.61-2.08)	0.704
BMI (≥20/ <20)	47/ 9	2.33 (1.07-5.08)	0.034
Stage (II/ III/ IV)	1/ 29/ 26	1.81 (1.02-3.20)	0.042
ECOG-ps (0/ 1/ 2)	20/ 24/ 12	1.62 (1.07-2.44)	0.021
Haemoglobin (≥12/ <12 g/dl)	33/ 22	1.87 (1.01-3.46)	0.047
White cell count (≤11/ >11 10^9/l)	44/ 12	2.42 (1.21-4.87)	0.013
IGF-I (μg/L) tertiles	102.01 (16.00-310.00)*	1.35 (0.93-1.95)	0.116
IGFBP-3 (ng/mL) tertiles	2147.38 (58.92-4881.09)*	1.27 (0.87-1.87)	0.215
IGF-I:IGFBP-3 tertiles	0.04 (0.02-0.27)*	1.02 (0.71-1.47)	0.913
Leptin (ug/l) tertiles	8.35 (1.00-103.00)*	0.78 (0.54-1.13)	0.194
Treatment (active/ palliative)	46/ 10	0.93 (0.41-2.09)	0.862
mGPS (0/ 1/ 2)	19/ 31/ 6	2.10 (1.30- 3.40)	0.002

*Median (range)

Table 2. Characteristics of patients with NSCLC grouped according to mGPS.

	mGPS 0 (n=19)	mGPS 1 (n=31)	mGPS 2 (n=6)	P- value
Age (<60/ ≥60 years)	3/ 16	7/ 24	1/ 5	0.768
Sex (M/ F)	12/ 7	17/ 14	5/ 1	0.699
BMI (≥20/ <20)	17/ 2	26/ 5	4/ 2	0.229
Stage (II/ III/ IV)	0/ 8/ 11	1/ 18/ 12	0/ 3/ 3	0.383
ECOG-ps (0/ 1/ 2)	9/ 8/ 2	9/ 14/ 8	2/ 2/ 2	0.143
Haemoglobin (≥12/ <12 g/dl)	16/ 3	16/ 14	1/ 5	0.002
White cell count (≤11/ >11 10^9/l)	15/ 4	26/ 5	3/ 3	0.358
IGF-I (ug/L) tertiles	7/ 9/ 3	10/ 7/ 14	1/ 4/ 1	0.292
IGFBP-3 (ng/mL) tertiles	2/ 8/ 9	13/ 11/ 7	3/ 1/ 2	0.035
IGF-I:IGFBP-3 tertiles	10/ 5/ 4	5/ 12/ 14	3/ 2/ 1	0.271
Leptin (ug/l) tertiles	6/ 6/ 6	7/ 12/ 12	5/ 0/ 0	0.174
Treatment (active/ palliative)	16/ 3	25/ 6	5/ 1	0.859